Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 14

1.

Abacavir, an anti-HIV-1 drug, targets TDP1-deficient adult T cell leukemia.

Tada K, Kobayashi M, Takiuchi Y, Iwai F, Sakamoto T, Nagata K, Shinohara M, Io K, Shirakawa K, Hishizawa M, Shindo K, Kadowaki N, Hirota K, Yamamoto J, Iwai S, Sasanuma H, Takeda S, Takaori-Kondo A.

Sci Adv. 2015 Apr 24;1(3):e1400203. doi: 10.1126/sciadv.1400203. eCollection 2015 Apr.

2.

Population pharmacokinetics of abacavir in pregnant women.

Fauchet F, Treluyer JM, Préta LH, Valade E, Pannier E, Urien S, Hirt D.

Antimicrob Agents Chemother. 2014 Oct;58(10):6287-9. doi: 10.1128/AAC.03469-14. Epub 2014 Jul 28.

3.

PharmGKB summary: abacavir pathway.

Barbarino JM, Kroetz DL, Altman RB, Klein TE.

Pharmacogenet Genomics. 2014 May;24(5):276-82. doi: 10.1097/FPC.0000000000000040. No abstract available.

4.

Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan.

Kurita T, Kitaichi T, Nagao T, Miura T, Kitazono Y.

Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):361-71. doi: 10.1002/pds.3589. Epub 2014 Mar 3.

5.

Antiretroviral bioanalysis methods of tissues and body biofluids.

DiFrancesco R, Maduke G, Patel R, Taylor CR, Morse GD.

Bioanalysis. 2013 Feb;5(3):351-68. doi: 10.4155/bio.12.319. Review.

6.

In vitro activity of antiretroviral drugs against Plasmodium falciparum.

Nsanzabana C, Rosenthal PJ.

Antimicrob Agents Chemother. 2011 Nov;55(11):5073-7. doi: 10.1128/AAC.05130-11. Epub 2011 Aug 29.

7.

Abacavir/lamivudine combination in the treatment of HIV: a review.

Sivasubramanian G, Frempong-Manso E, Macarthur RD.

Ther Clin Risk Manag. 2010 Mar 3;6:83-94.

8.

Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.

Achenbach CJ, Scarsi KK, Murphy RL.

Adv Ther. 2010 Jan;27(1):1-16. doi: 10.1007/s12325-010-0006-9. Epub 2010 Mar 5. Review. Erratum in: Adv Ther. 2010 Feb;27(2):127.

9.

Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.

Cross SJ, Rodman JH, Lindsey JC, Robbins BL, Rose CH, Yuen GJ, D'angelo LJ.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):54-9. doi: 10.1097/QAI.0b013e31819a2257.

10.

Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.

Sleasman JW, Robbins BL, Cross SJ, Lindsey JC, Kraimer JM, Heckman BE, Sprenger HL, Tustin NB, Rose CH, Poston PA, Neal EF, Pakes GE, Nikanjam M, Capparelli EV.

Clin Pharmacol Ther. 2009 Apr;85(4):394-401. doi: 10.1038/clpt.2008.236. Epub 2008 Dec 31.

11.

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.

Capparelli EV, Letendre SL, Ellis RJ, Patel P, Holland D, McCutchan JA.

Antimicrob Agents Chemother. 2005 Jun;49(6):2504-6.

12.

Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

Jullien V, Tréluyer JM, Chappuy H, Dimet J, Rey E, Dupin N, Salmon D, Pons G, Urien S.

Br J Clin Pharmacol. 2005 Feb;59(2):183-8.

13.

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.

DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD; Adult AIDS Clinical Trials Group Protocol 368/886 Study Team.

Antimicrob Agents Chemother. 2003 Jun;47(6):1929-35.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk